Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial

被引：1

作者：

Park, H. ^{[1
]}

Sanjeevaiah, A. ^{[2
]}

Suresh, R. ^{[1
]}

Mehta, R. ^{[3
]}

Trikalinos, N. ^{[1
]}

Bagegni, N. ^{[1
]}

Aranha, O. ^{[1
]}

Pedersen, K. ^{[1
]}

Nixon, A. ^{[4
]}

Jin, R. ^{[1
]}

Mills, J. ^{[1
]}

Fields, R. ^{[1
]}

Amin, M.

Lim, K.

Tan, B. ^{[1
]}

Grierson, P. ^{[1
]}

Jiang, S. ^{[1
]}

del Rosario, M. ^{[1
]}

Wang-Gillam, A. ^{[1
]}

Lockhart, A. ^{[5
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] UT Southwestern Med Ctr, Dallas, TX USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Duke Univ, Med Ctr, Durham, NC 27706 USA

[5] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.213

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-131

引用

页码：S132 / S132

页数：1

共 50 条

[41] Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Wang, Zhiqiang
Chen, Dongliang
Li, Hongli
Yang, Mudan
Lin, Rongbo
Cheng, Ying
Li, Zhiwei
Huang, Xiwen
Wang, Wei
Li, Hui
Liu, Hao
Dai, Youguo
Wang, Jufeng
Zhao, Xin
Yang, Yan
Qu, Xiujuan
Zhao, Jun
Zhang, Zhe
Zeng, Yanyan
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies
不详
JOURNAL OF THORACIC DISEASE, 2015, 7
[43] A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia
Hocepied, AMLJ
Falkson, CI
Falkson, G
SOUTH AFRICAN MEDICAL JOURNAL, 1996, 86 (05): : 549 - 550
[44] Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
Burris, HA
Rivkin, S
Reynolds, R
Harris, J
Wax, A
Gerstein, H
Mettinger, KL
Staddon, A
ONCOLOGIST, 2005, 10 (03): : 183 - 190
[45] Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane.
Sagawa, Tamotsu
Satake, Hironaga
Fujikawa, Koshi
Hatachi, Yukimasa
Yasui, Hisateru
Kotaka, Masahito
Kato, Takeshi
Tsuji, Akihito
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[46] A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603
O'Reilly, E. M.
Niedzwiecki, D.
Hollis, D. R.
Bekaii-Saab, T. S.
Pluard, T.
Duffy, A.
Overcash, F.
Ivy, S. P.
Goldberg, R. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47] Berzosertib plus irinotecan in patients with TP53 mutant gastric/gastroesophageal junction adenocarcinoma: A phase II study
Das, Satya
Ayers, G. Dan
Whisenant, Jennifer
Saeed, Anwaar
Kim, Edward
Florou, Vaia
Yacoub, George
Ivy, Percy
Kunos, Charles
Berlin, Jordan
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[48] A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
Burge, ME
Smith, D
Topham, C
Jackson, DP
Anthoney, DA
Halstead, F
Seymour, MT
BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1281 - 1286
[49] A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
M E Burge
D Smith
C Topham
D P Jackson
D A Anthoney
F Halstead
M T Seymour
British Journal of Cancer, 2006, 94 : 1281 - 1286
[50] Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
Qu, Jinglei
He, Xin
Luo, Ying
Yu, Ping
Chen, Ying
Liu, Jing
Wang, Xin
Wang, Chang
Liang, Tingting
Bai, Yuxian
Han, Yu
Man, Li
Leng, Chuanchun
Zhou, Caiyun
He, Lijie
Liu, Yunpeng
Qu, Xiujuan
FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 →